Unterehmen auf Watchlist setzen
Pulse Biosciences
ISIN: US74587B1017
WKN: A2AMY9
Curious about what AI knows about Pulse Biosciences? Just one click more
More AI Integrations
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Pulse Biosciences · ISIN: US74587B1017 · Business Wire (ID: 20250304049146)
04 März 2025 02:00PM

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to 14 new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan. The equity awards were approved and issued on February 27, 2025 and March 3, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to 14 new employees to purchase up to 165,300 shares of Company common stock. The Company’s independent compensation committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of either $18.34 or $17.87 per share, which is equal to the closing price of the Company’s common stock on February 27, 2025 and March 3, 2025, respectively, and all will be subject to time-based vesting over four years, with 1/4 of each award vesting annually, subject to the employee’s continued employment with Pulse Biosciences. The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements entered into with each recipient.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Contact

Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com

Or

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Visuelle Wertentwicklung / Kursverlauf · Pulse Biosciences
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
MIC: XNAS
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2025
BusinessWire
Kontakt:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422